



PTO/SB/08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |                   |
|---|---|----|---|--------------------------|-------------------|
| <b>Substitute for form 1449A/PTO</b><br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |   |    |   | <b>Complete if Known</b> |                   |
|   |   |    |   | Application Number       | 10/804,668        |
|   |   |    |   | Filing Date              | March 19, 2004    |
|   |   |    |   | First Named Inventor     | William A. Zoghbi |
|   |   |    |   | Art Unit                 | N/A               |
|   |   |    |   | Examiner Name            | Not Yet Assigned  |
| Sheet   | 1 | of | 3 | Attorney Docket Number   | HO-P02680US1      |

| U.S. PATENT DOCUMENTS |                       |  |                                |  |  |
|-----------------------|-----------------------|--|--------------------------------|--|--|
| Examiner Initials*    | Cite No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant<br>of Cited Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear |
|                       |                       | Number-Kind Code <sup>2</sup> (if known) |                                |  |  |
|                       | AA                    | US-US 2003/0022235                       | 01-30-2003                     | Dahlen et al.                                      |  |
|                       | AB                    | US-US 2003/0045908                       | 03-06-2003                     | Condie et al.                                      |  |
|                       | AC                    | US-5,756,067                             | 05-26-1998                     | Jones  |  |
|                       | AD                    | US-6,162,902                             | 12/2000                        | Mischak et al.                                     |  |
|                       | AE                    | US-6,322,771                             | 11-27-2001                     | Linden et al.                                      |  |
|                       | AF                    | US-6,376,207                             | 04-23-2002                     | Nolan  |  |
|                       | AG                    | US-6,461,828                             | 10-08-2002                     | Stanton, et al.                                    |  |

| FOREIGN PATENT DOCUMENTS |                       |   |                                |  |  |                |
|--------------------------|-----------------------|---|--------------------------------|--|--|----------------|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>6</sup> |
|                          |                       | Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known) |                                |  |  |                |
|                          | BA                    | WO-WO 2002089657  | 05-04-2002                     | Biosite, Inc.                                      |  |                |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.  | T <sup>2</sup> |
|                                 | CA                    | Axis-Shield - News Article - BNP TESTS 9/17/02 OTA#02/093, "New Test Used to Spot Heart Failure"; Dallas Business Journal, v25n11, 2001-10-06   |                |
|                                 | CB                    | BERGER, R. ET AL, "B-Type Natriuretic Peptides (BNP and Pro-BNP) Predict Longterm Survival in Patients with Advanced Heart Failure Treated with Atenolol"; J Heatt Lung Transplant. 20,251 (2001)   |                |
|                                 | CC                    | BROCKHOFF C, ET AL; "Atrial natriuretic peptides: diagnostic and therapeutic poeetnial" - Article in German - Abteilung fur Kardiologie, Universitatskrankenhaus Eppendorf, Hamburg, Germany; 4/8/2002  |                |
|                                 | CD                    | CHO Y, ET AL.; "Natriuretic peptides and their therapeutic potential"; 4/8/2002; Department of Medicine, Brown University School of Medicine, Providence, Rhode Island, USA   |                |
|                                 | CE                    | CLERICO A, ET AL.; "Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in a clinical practice: the need for a new generation of immunoassay methods"; Laboratory of Cardiovascular Endocrinology, Consiglio Nazionale delle Ricerche Institute of Clinical Physiology, University of Pisa, Pisa, Italy; 4/8/2002 |                |
|                                 | CF                    | COWIE MR; "BNP: soon to become a routine measure in the care of patients with heart failure?"; 4/8/2002   |                |
|                                 | CG                    | DE LEMOS, J.A., ET AL., "The Prognostic Value of B-Type Natriuretic Peptide in Patients with  |                |

|          |  |                 |  |
|----------|--|-----------------|--|
| 25535526 |  | Date Considered |  |
| .1       |  |                 |  |

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |                   |
|---|---|----|---|--------------------------|-------------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |                   |
|   |   |    |   | Application Number       | 10/804,668        |
|   |   |    |   | Filing Date              | March 19, 2004    |
|   |   |    |   | First Named Inventor     | William A. Zoghbi |
|   |   |    |   | Art Unit                 | N/A               |
|   |   |    |   | Examiner Name            | Not Yet Assigned  |
| Sheet   | 2 | of | 3 | Attorney Docket Number   | HO-P02680US1      |

|  |    |   |  |
|--|----|---|--|
|  |    | Acute Coronary Syndromes"; N Engl J Med.. 345, 1014-21 (2001)   |  |
|  | CH | DIAGNOSING HEART DISEASE ( <a href="http://www.americanheart.org">http://www.americanheart.org</a> ) September 17, 2002 - ABOUT RESEARCH; About VA R&D: News Releases About VA Research: Blood test for heart failure scores big in multinational trial   |  |
|  | CI | DOOLITTLE, M.H. ET AL., "Immunodetection of Lipoprotein Lipase: Antibody Production, Immunoprecipitation, and Western Blotting Techniques"; Methods Mol Biol. 109, 215-371 (1999)   |  |
|  | CJ | FISCHER, Y. ET AL., "Evaluation of a New, Rapid Bedside Test for Quantitative Determination of B-Type Natriuretic Peptide", Clin. Chem. 47, 591-594 (2001)  |  |
|  | CK | JOURDAIN P, ET AL.; "Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol."; Service de Cardiologie Hopital R. Dubos, Pontoise, France; 11/21/2002   |  |
|  | CL | KATO M, ET AL., "Augmented response in plasma brain natriuretic peptide to dynamic exercise in patients with left ventricular dysfunction and congestive heart failure."; 1st Department of Internal Medicine, Tottori University Faculty of Medicine, Yonago, Japan; 11/21/2002  |  |
|  | CM | LATINI R, ET AL.; "What does the future hold for BNP in cardiology?"; 2/8/2002  |  |
|  | CN | LEDER, ET AL.; "Myocardial ischemia and viability"; Clinic of Internal Medicine, Biomagnetic Centre, University of Jena, Jena, Germany (no date)  |  |
|  | CO | MAIR J, ET AL.; "The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure"; Department of Internal Medicine, University of Innsbruck School of Medicine, Austria; 4/8/2002  |  |
|  | CP | MARUMOTO K, ET AL., "Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris"; Clin Sci (Lond); 88: 551-556 (1995)  |  |
|  | CQ | MCNAIRY M, ET AL.; "Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide."; ; Division of Cardiology and the Department of Medicine, Veteran's Affairs medical Center and University of California, San Diego, California; 11/21/2002 |  |
|  | CR | NAGEH T, ET AL.; "Interpretation of plasma brain natriuretic peptide concentrations may require adjustment for patient's age."; 4/8/2002; Department of Cardiology, King's College Hospital, London, UK   |  |
|  | CS | NAKAMURA M, ET AL.; "Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population"; 4/8/2002   |  |
|  | CT | NICHOLSON S, ET AL.; "Atrial and brain natriuretic peptide response to exercise in pateints with ischaemic heart disease"; 11/21/2002   |  |
|  | CU | NISHIKIMI T, ET AL.; "Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease."; Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Mibu, Tochigi, Japan; 4/19/2002  |  |
|  | CV | OHBA H, ET AL.; "Effects of prolonged strenuous exercise on plasma levels of atrial natriuretic peptide and brain natriuretic peptide in healthy men"; Department of Cardiology, St. Mariana University School of Medicine, Kanagawa, Japan; 4/19/2002  |  |
|  | CW | OMLAND, T., "Plasma Brain Natriuretic Peptide as an Indicator of Left Ventricular Systolic Function and Long-term survival After Acute Myocardial Infarction", Circulation 1;93(11), 1963-9 (1996)  |  |

|                |  |                    |  |
|----------------|--|--------------------|--|
| 25535526<br>.1 |  | Date<br>Considered |  |
|----------------|--|--------------------|--|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |                   |
|---|---|----|---|--------------------------|-------------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |                   |
|   |   |    |   | Application Number       | 10/804,668        |
|   |   |    |   | Filing Date              | March 19, 2004    |
|   |   |    |   | First Named Inventor     | William A. Zoghbi |
|   |   |    |   | Art Unit                 | N/A               |
|   |   |    |   | Examiner Name            | Not Yet Assigned  |
| Sheet   | 3 | of | 3 | Attorney Docket Number   | HO-P02680US1      |

|  |     |  |  |
|--|-----|--|--|
|  | CX  | PEACOCK WF 4TH; "The B-type natriuretic peptide assay: a rapid test for heart failure"; 4/8/2002   |  |
|  | CY  | STEIN, B., "Natriuretic peptides; Physiology, therapeutic potential, and risk stratification in ischemic heart disease"; C. Am Heart J. 135 (5Pt 1), 914-23 (1998)                                   |  |
|  | CZ  | VA Research Communications Service; "Quick Blood Test for Heart Failure Proves Successful in Multinational Trial"; Public Release Date 17 Jul 2002   |  |
|  | CA1 | VENUGOPAL J; "Cardiac natriuretic peptides—hope or hype?"; Department of Physiology and Pharmacology, Strathclyde Institute of Biomedical Sciences, University of Strathclyde, Glasgow, UK; 4/8/2002 |  |
|  | CB1 | WAKU S, ET AL.; "Significance of brain natriuretic peptide measurement as a diagnostic indicator of cardiac function"; Kansai University, Health Administration Center, Osaka, Japan; 4/8/2002       |  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

|                |  |                    |  |
|----------------|--|--------------------|--|
| 25535526<br>.1 |  | Date<br>Considered |  |
|----------------|--|--------------------|--|